Shares of Aeterna Zentaris (AEZS 0.77%) were gutted on the market Monday, down 25% intraday. In this video, Motley Fool health-care analyst David Williamson takes a look at a horrendous 12-month period for the company overall, and how hanging its hopes on its drug Perifosine has resulted in disappointment after disappointment in clinical trials.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.